Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia

Label Expansion Includes New Data Showing Long-Term VRAYLAR Therapy Delayed Time to Relapse Compared to Placebo Over the Course of up to 72 Weeks DUBLIN, Nov. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Allergan plc (NYSE: AGN) today announce... Biopharmaceuticals, Neurology, FDA Allergan, VRAYLAR, cariprazine, Schizophrenia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news